AGPAT9
Glycerol-3-phosphate acyltransferase 3 (GPAT-3) is an enzyme that in humans is encoded by the AGPAT9 gene.[1][2][3][4] GPAT-3 is also known as:
- 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9),
- lysophosphatidic acid acyltransferase theta (LPAAT-theta), or
- lung cancer metastasis-associated protein 1.
Function
Function
Glycerol-3-phosphate (G3P) acyltransferases (GPAT; EC 2.3.1.15), such as GPAM and GPAT3 (this enzyme), catalyze the initial step of de novo triacylglycerol (TAG) synthesis by converting glycerol-3-phosphate (G3P) to lysophosphatidic acid (LPA).[2]
References
References
- ↑ Clark HF, Gurney AL, Abaya E, et al. (October 2003). “The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment”. Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
- ↑ 2.0 2.1 Cao J, Li JL, Li D, Tobin JF, Gimeno RE (December 2006). “Molecular identification of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de novo triacylglycerol synthesis”. Proc. Natl. Acad. Sci. U.S.A. 103 (52): 19695–700. doi:10.1073/pnas.0609140103. PMC 1702318. PMID 17170135.
- ↑ Tang W, Yuan J, Chen X, Gu X, Luo K, Li J, Wan B, Wang Y, Yu L (September 2006). “Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway”. J. Biochem. Mol. Biol. 39 (5): 626–35. doi:10.5483/BMBRep.2006.39.5.626. PMID 17002884.
- ↑ “Entrez Gene: AGPAT9: 1-acylglycerol-3-phosphate O-acyltransferase 9”.
External links
External links
- Human GPAT3 genome location and GPAT3 gene details page in the UCSC Genome Browser.
Further reading
Further reading
- Tang W, Yuan J, Chen X, et al. (2006). “Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway”. J. Biochem. Mol. Biol. 39 (5): 626–35. doi:10.5483/BMBRep.2006.39.5.626. PMID 17002884.
- Yamada S, Ohira M, Horie H, et al. (2004). “Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas”. Oncogene. 23 (35): 5901–11. doi:10.1038/sj.onc.1207782. PMID 15221005.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). “Construction and characterization of a full length-enriched and a 5′-end-enriched cDNA library”. Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Maruyama K, Sugano S (1994). “Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides”. Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH